SIGA SIGA TECHNOLOGIES INC

Nasdaq Pharmaceutical Preparations DE CIK: 0001010086
AI RATING
HOLD
75% Confidence

Investment Thesis

SIGA demonstrates financial resilience with exceptional balance sheet strength ($155M cash, minimal debt) and robust free cash flow generation (45.9% FCF margin), positioning it to weather current challenges. However, the company faces significant operational headwinds with revenue declining 31.8% YoY and net income collapsing 60.7%, driven likely by lumpy government contract dependence in the biodefense sector, requiring evidence of revenue stabilization before turning positive.

Strengths

  • + Fortress balance sheet with $155M cash against only $20.6M liabilities and 11.83x current ratio
  • + Outstanding free cash flow generation of $43.4M with 45.9% FCF margin despite revenue decline
  • + Healthy operating margin of 25.1% maintained through disciplined cost management

Risks

  • ! Severe revenue contraction of 31.8% YoY with net income declining 60.7%, signaling structural margin compression or significant one-time charges
  • ! Business model heavily dependent on lumpy, contract-driven government procurement (antiviral/biodefense), creating unpredictable cash flow patterns
  • ! Long-term debt of $78.9M represents contingent liability that warrants monitoring if revenue decline continues

Key Metrics to Watch

Financial Metrics

Revenue
94.6M
Net Income
23.3M
EPS (Diluted)
$0.32
Free Cash Flow
43.4M
Total Assets
219.5M
Cash
155.0M

Profitability Ratios

Gross Margin N/A
Operating Margin 25.1%
Net Margin 24.6%
ROE 11.7%
ROA 10.6%
FCF Margin 45.9%

Balance Sheet & Liquidity

Current Ratio
11.83x
Quick Ratio
9.10x
Debt/Equity
0.40x
Debt/Assets
9.4%
Interest Coverage
N/A
Long-term Debt
78.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-15T21:48:21.613096 | Data as of: 2025-12-31 | Powered by Claude AI